Eli Lilly Canada (LLY) Announces Health Canada has approved TALTZ for Treatment of Active Ankylosing Spondylitis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Health Canada has approved TALTZ® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
February 11, 2020 6:45 AM ESTTORONTO, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Eli Lilly Canada announced today that Health Canada approved TALTZ® (ixekizumab) on February 4, 2020, for the treatment of adult patients with active ankylosing spondylitis (AS), which is also known as radiographic axial spondyloarthritis (r-axSpA), who have responded inadequately to, or are intolerant to, conventional therapy. This is the third indication for TALTZ, which was first approved by Health Canada for moderate- to severe plaque psoriasis and psoriatic arthritis in 2016 and 2018, respectively.
People living with ankylosing spondylitis deal with a considerable amount of pain and anxiety. If left untreated, it can severely affect... More
